Synmosa Biopharma Corporation Stock

Equities

4114

TW0004114004

Pharmaceuticals

End-of-day quote Taipei Exchange 18:00:00 2024-05-23 EDT 5-day change 1st Jan Change
39.55 TWD +0.13% Intraday chart for Synmosa Biopharma Corporation -1.74% +2.33%

Financials

Sales 2022 4.39B 136M 186M Sales 2023 5.14B 159M 218M Capitalization 14.71B 456M 623M
Net income 2022 799M 24.79M 33.83M Net income 2023 595M 18.46M 25.19M EV / Sales 2022 4.09 x
Net Debt 2022 1.94B 60.11M 82.02M Net Debt 2023 783M 24.28M 33.13M EV / Sales 2023 3.01 x
P/E ratio 2022
19.9 x
P/E ratio 2023
24 x
Employees -
Yield 2022
1.14%
Yield 2023
1.55%
Free-Float 81.1%
More Fundamentals * Assessed data
Dynamic Chart
Synmosa Biopharma Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Synmosa Biopharma Corporation Announces Changes in Fifth Session of the Remuneration Committee CI
Synmosa Biopharma Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Synmosa Biopharma Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Synmosa Biopharma Corporation Announces Cash Dividend, Payable on September 15, 2023 CI
Synmosa Biopharma Corporation Appoints Tu, San-Chien as Additional Independent Director CI
Synmosa Biopharma Corporation Appoints Tu, San-Chien as Member of the Audit Committee CI
Synmosa Biopharma Corporation announced that it expects to receive TWD 950 million in funding CI
Synmosa Biopharma Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Synmosa Biopharma Corporation Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Synmosa Biopharma Corporation Approves Dividend for the Year Ended December 31, 2022 CI
Synmosa Biopharma Corporation Announces Changes of Corporate Governance Officer CI
Synmosa Biopharma Corporation Provides Earnings Guidance for the Year 2022 CI
Synmosa Biopharma Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Synmosa Biopharma Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
More news
1 day+0.13%
1 week-1.74%
Current month+2.59%
1 month+3.53%
3 months+2.73%
6 months+4.63%
Current year+2.33%
More quotes
1 week
39.25
Extreme 39.25
41.00
1 month
38.10
Extreme 38.1
41.00
Current year
36.95
Extreme 36.95
41.00
1 year
34.90
Extreme 34.9
43.70
3 years
18.01
Extreme 18.0108
51.06
5 years
10.42
Extreme 10.4246
51.06
10 years
10.42
Extreme 10.4246
51.06
More quotes
Managers TitleAgeSince
Chief Executive Officer - 70-08-24
Director of Finance/CFO - 01-03-31
Corporate Officer/Principal - -
Members of the board TitleAgeSince
Chief Executive Officer - 70-08-24
Director/Board Member 41 19-05-23
Director/Board Member 51 19-05-23
More insiders
Date Price Change Volume
24-05-24 39.55 +0.13% 630,234
24-05-23 39.5 -1.13% 1,575,434
24-05-22 39.95 -0.99% 1,635,432
24-05-21 40.35 +0.12% 1,470,415
24-05-20 40.3 +0.12% 3,172,784

End-of-day quote Taipei Exchange, May 23, 2024

More quotes
SYNMOSA BIOPHARMA CORPORATION is a Taiwan-based company principally engaged in the manufacture and sales of various kinds of pharmaceuticals and medical equipment. The Company's main products include respiratory drugs, cardiovascular and urinary drugs, gastrointestinal drugs, hormones, anti-tumor drugs, antibiotics and health products. The Company is also involved in the manufacture and sales of various kinds of cosmetics and animal medicines, as well as various kinds of chemical food additives and beverages. The Company distributes its products in domestic market and to overseas markets.
More about the company

Quarterly revenue - Rate of surprise